Erasing cancer, reviving oncolytic virus, treating a rare neuromuscular condition: Here's what you need to know about the 5 new biotechs filing for IPOs
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
Last week was a busy one for biotech IPOs, with five more companies filing to go public just before the start of the weekend, including a company led by GlaxoSmithKline vet Paul Peter Tak that’s been working on oncolytic viruses for decades, and a quiet San Diego-based upstart that’s jumping into the spotlight with 11 programs coming down the pipeline. Each of them penciled in a $100 million dollar raise — but if trends continue, they could go on to raise much, much more.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.